Neurontin 250 mg in 5 mL Oral Solution
RxNorm 351973
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 351973 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Neurontin 250 mg in 5 mL Oral Solution.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Gabapentin 50 mg/ML Oral Solution [Neurontin]
(Atom ID: 1550089)
PSNPrescribable
Prescribable Name (PSN):
Neurontin 250 mg in 5 mL Oral Solution
(Atom ID: 8261006)
SYPrescribable
Synonym (SY):
Neurontin 250 mg per 5 mL Oral Solution
(Atom ID: 3801088)
SYPrescribable
Synonym (SY):
Neurontin 50 mg/ML Oral Solution
(Atom ID: 1550091)
Patient Education
Gabapentin
Gabapentin capsules, tablets, and oral solution are used along with other medications to help control certain types of seizures in people who have epilepsy. Gabapentin capsules, tablets, and oral solution are also used to relieve the pain of postherpetic neuralgia (PHN; the burning, stabbing pain or aches that may last for months or years after an attack of shingles). Gabapentin extended-release tablets (Horizant) are used to treat restless legs syndrome (RLS; a condition that causes discomfort in the legs and a strong urge to move the legs, especially at night and when sitting or lying down). Gabapentin is in a class of medications called anticonvulsants. Gabapentin treats seizures by decreasing abnormal excitement in the brain. Gabapentin relieves the pain of PHN by changing the way the body senses pain. It is not known exactly how gabapentin works to treat restless legs syndrome.
[Learn More]
* Please review the disclaimer below.